24
Apr

AstraZeneca is continuing its campaign to refashion its image as it tries to shake off past setbacks and unsuccessful units and turn analysts’ attention to its brightest pipeline prospects, particularly in cancer.

…read more

Source: AstraZeneca continues to chop back, spotlights immuno-oncology PhIII

    

0 No comments